Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3)
Well-differentiated grade 3 neuroendocrine tumors (NET G3) have been distinguished from poorly differentiated neuroendocrine carcinomas (NEC) in the most current WHO classifications. Commonly applied first-line chemotherapy protocols with cisplatin or carboplatin in combination with etoposide (PE) a...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
16 April 2021
|
| In: |
Cancers
Year: 2021, Jahrgang: 13, Heft: 8, Pages: 1-14 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13081936 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers13081936 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/13/8/1936 
|
| Verfasserangaben: | Leonidas Apostolidis, Arianna Dal Buono, Elettra Merola, Henning Jann, Dirk Jäger, Bertram Wiedenmann, Eva Caroline Winkler and Marianne Pavel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1760368792 | ||
| 003 | DE-627 | ||
| 005 | 20220819230200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210614s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13081936 |2 doi | |
| 035 | |a (DE-627)1760368792 | ||
| 035 | |a (DE-599)KXP1760368792 | ||
| 035 | |a (OCoLC)1341415364 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Apostolidis, Leonidas |d 1981- |e VerfasserIn |0 (DE-588)139136932 |0 (DE-627)703220594 |0 (DE-576)309798590 |4 aut | |
| 245 | 1 | 0 | |a Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3) |c Leonidas Apostolidis, Arianna Dal Buono, Elettra Merola, Henning Jann, Dirk Jäger, Bertram Wiedenmann, Eva Caroline Winkler and Marianne Pavel |
| 264 | 1 | |c 16 April 2021 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.06.2021 | ||
| 520 | |a Well-differentiated grade 3 neuroendocrine tumors (NET G3) have been distinguished from poorly differentiated neuroendocrine carcinomas (NEC) in the most current WHO classifications. Commonly applied first-line chemotherapy protocols with cisplatin or carboplatin in combination with etoposide (PE) are less effective in NET G3 than NEC. Suggested alternative treatment protocols have not been studied in first-line therapy of NET G3 so far. We performed a retrospective analysis of patients with NET G3 in the databases of 3 German cancer centers. Out of 142 patients, 136 patients received palliative first-line therapy: overall response rate (ORR) was 35.1% for PE (n = 37), 56.4% for FOLFOX (n = 39), 27.3% for temozolomide/capecitabine (TEM/CAP) (n = 22), 45.0% for streptozotocin/5-fluorouracil (STZ/5-FU) (n = 20), and 16.7% for other (n = 18). Median progression-free survival (PFS) for PE was 6.9 months. Compared to PE, PFS in the other treatment groups was 6.9 months for FOLFOX (p = 0.333), 12.0 months for TEM/CAP (p = 0.093), 4.8 months for STZ/5-FU (p = 0.919), and 14.1 months for other (p = 0.014). In a univariate setting, all non-PE patients combined showed a significantly prolonged PFS vs. PE (9.0 months; p = 0.049) which could not be confirmed in a multivariate analysis. In conclusion, NET G3 with FOLFOX showed the highest ORR, and with TEM/CAP showed the longest PFS. Further prospective evaluation of the optimal therapeutic strategy for this tumor entity is needed. | ||
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a first-line | |
| 650 | 4 | |a NET G3 | |
| 650 | 4 | |a neuroendocrine carcinoma | |
| 650 | 4 | |a neuroendocrine tumor | |
| 650 | 4 | |a peptide receptor radionuclide therapy | |
| 650 | 4 | |a systemic therapy | |
| 700 | 1 | |a Dal Buono, Arianna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Merola, Elettra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jann, Henning |e VerfasserIn |0 (DE-588)1119177332 |0 (DE-627)872479811 |0 (DE-576)479761590 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Wiedenmann, Bertram |e VerfasserIn |0 (DE-588)1112471812 |0 (DE-627)866442847 |0 (DE-576)47658714X |4 aut | |
| 700 | 1 | |a Winkler, Eva C. |d 1971- |e VerfasserIn |0 (DE-588)1055853065 |0 (DE-627)792734823 |0 (DE-576)411905384 |4 aut | |
| 700 | 1 | |a Pavel, Marianne |d 1965- |e VerfasserIn |0 (DE-588)120555336 |0 (DE-627)080745156 |0 (DE-576)292275552 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 13(2021), 8, Artikel-ID 1936, Seite 1-14 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3) |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:8 |g elocationid:1936 |g pages:1-14 |g extent:14 |a Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3) |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13081936 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/8/1936 |x Verlag |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20210614 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1055853065 |a Winkler, Eva C. |m 1055853065:Winkler, Eva C. |d 910000 |d 912900 |d 50000 |e 910000PW1055853065 |e 912900PW1055853065 |e 50000PW1055853065 |k 0/910000/ |k 1/910000/912900/ |k 0/50000/ |p 7 | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 5 | ||
| 998 | |g 139136932 |a Apostolidis, Leonidas |m 139136932:Apostolidis, Leonidas |d 910000 |d 910100 |e 910000PA139136932 |e 910100PA139136932 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1760368792 |e 3938028807 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"given":"Leonidas","role":"aut","display":"Apostolidis, Leonidas","family":"Apostolidis"},{"role":"aut","given":"Arianna","display":"Dal Buono, Arianna","family":"Dal Buono"},{"family":"Merola","display":"Merola, Elettra","given":"Elettra","role":"aut"},{"given":"Henning","role":"aut","display":"Jann, Henning","family":"Jann"},{"given":"Dirk","role":"aut","display":"Jäger, Dirk","family":"Jäger"},{"role":"aut","given":"Bertram","family":"Wiedenmann","display":"Wiedenmann, Bertram"},{"role":"aut","given":"Eva C.","family":"Winkler","display":"Winkler, Eva C."},{"given":"Marianne","role":"aut","family":"Pavel","display":"Pavel, Marianne"}],"recId":"1760368792","relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3)Cancers","origin":[{"publisherPlace":"Basel","dateIssuedDisp":"2009-","publisher":"MDPI","dateIssuedKey":"2009"}],"pubHistory":["1.2009 -"],"note":["Gesehen am 27.05.2020"],"title":[{"title_sort":"Cancers","title":"Cancers"}],"id":{"eki":["614095670"],"issn":["2072-6694"],"zdb":["2527080-1"]},"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"614095670","part":{"volume":"13","extent":"14","text":"13(2021), 8, Artikel-ID 1936, Seite 1-14","issue":"8","pages":"1-14","year":"2021"},"language":["eng"]}],"physDesc":[{"extent":"14 S."}],"name":{"displayForm":["Leonidas Apostolidis, Arianna Dal Buono, Elettra Merola, Henning Jann, Dirk Jäger, Bertram Wiedenmann, Eva Caroline Winkler and Marianne Pavel"]},"id":{"eki":["1760368792"],"doi":["10.3390/cancers13081936"]},"title":[{"title_sort":"Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3)","title":"Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3)"}],"origin":[{"dateIssuedDisp":"16 April 2021","dateIssuedKey":"2021"}],"note":["Gesehen am 14.06.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a APOSTOLIDIMULTICENTE1620 | ||